Lupus is a complex heterogeneous disease characterised by autoantibody production and immune complex deposition followed by damage to target tissues. Animal models of human diseases are an invaluable tool for defining pathogenic mechanisms and testing of novel therapeutic agents. There are perhaps more applicable murine models of lupus than any other human disease. There are spontaneous models of lupus, inducible models of lupus, transgenic-induced lupus, gene knockout induced lupus and humanised mouse models of lupus. These mouse models of lupus have contributed significantly to our knowledge of the pathogenesis of lupus and served as valuable preclinical models for proof of concept for new therapies. Despite their utility, mouse models of lupus have their distinct limitations. Although similar, mouse and human immune systems are different and thus one cannot assume a mechanism for disease in one is translatable to the other. Efficacy and toxicity of compounds can vary significantly between humans and mice, also limiting direct translation. Finally, the heterogeneous aspects of human lupus, both in clinical presentation, underlying pathogenesis and genetics, are not completely represented in current mouse models. Thus, proving a therapy or mechanism of disease in one mouse model is similar to proving a mechanism/therapy in a limited subset of human lupus. These limitations, however, do not marginalise the importance of animal models nor the significant contributions they have made to our understanding of lupus.
Objective: The Fli‐1 transcription factor is implicated in the pathogenesis of systemic lupus erythematosus (SLE), both in humans and in animal models. Dysregulation of interleukin‐6 (IL‐6) is also associated with SLE. The purpose of this study was to investigate whether Fli‐1 directly regulates the expression of IL‐6.Methods: Sera were collected from wild‐type and Fli‐1–heterozygous (Fli‐1+/−) MRL/lpr mice, and the concentration of IL‐6 was measured by enzyme‐linked immunosorbent assay (ELISA). Expression of IL‐6 in the kidney was measured by real‐time polymerase chain reaction analysis. T cells were isolated from wild‐type and Fli‐1+/− MRL/lpr mice and stimulated with CD3/CD28 beads, and the concentration of IL‐6 in the supernatants was measured by ELISA. MS1 endothelial cells were transfected with Fli‐1 and control small interfering RNA, and the production of IL‐6 was compared after lipopolysaccharide stimulation. A chromatin immunoprecipitation (ChIP) assay was performed to determine whether Fli‐1 binds to the IL‐6 promoter region. Transient transfections with the NIH3T3 cell line were performed to examine whether Fli‐1 regulates the expression of IL‐6.Results: Fli‐1+/− MRL/lpr mice had significantly decreased IL‐6 levels in sera and reduced expression of IL‐6 in kidneys as compared to their wild‐type littermates. T cells isolated from Fli‐1+/− MRL/lpr mice produced less IL‐6 than did those from wild‐type mice. Inhibiting the expression of Fli‐1 in endothelial cells resulted in reduced production of IL‐6. The ChIP assay revealed direct binding of Fli‐1 to 3 regions within the IL‐6 promoter. Fli‐1 activated transcription from the IL‐6 promoter in a dose‐dependent manner.Conclusion: The direct regulation of IL‐6 expression by Fli‐1 represents one possible mechanism for the protective effect of decreased Fli‐1 expression in lupus.
The friend leukemia insertion site 1 (Fli-1) transcription factor, an Ets family member, is implicated in the pathogenesis of systemic lupus erythematosus in human patients and murine models of lupus. Lupus-prone mice with reduced Fli-1 expression have significantly less nephritis, prolonged survival, and decreased infiltrating inflammatory cells into the kidney. Inflammatory chemokines, including CCL5, are critical for attracting inflammatory cells. In this study, decreased CCL5 mRNA expression was observed in kidneys of lupus-prone NZM2410 mice with reduced Fli-1 expression. CCL5 protein expression was significantly decreased in endothelial cells transfected with Fli-1–specific small interfering RNA compared with controls. Fli-1 binds to endogenous Ets binding sites in the distal region of the CCL5 promoter. Transient transfection assays demonstrate that Fli-1 drives transcription from the CCL5 promoter in a dose-dependent manner. Both Ets1, another Ets family member, and Fli-1 drive transcription from the CCL5 promoter, although Fli-1 transactivation was significantly stronger. Ets1 acts as a dominant-negative transcription factor for Fli-1, indicating that they may have at least one DNA binding site in common. Systematic deletion of DNA binding sites demonstrates the importance of the sites located within a 225-bp region of the promoter. Mutation of the Fli-1 DNA binding domain significantly reduces transactivation of the CCL5 promoter by Fli-1. We identified a novel regulator of transcription for CCL5. These results suggest that Fli-1 is a novel and critical regulator of proinflammatory chemokines and affects the pathogenesis of disease through the regulation of factors that recruit inflammatory cells to sites of inflammation.